schliessen

Filtern

 

Bibliotheken

Serum connective tissue growth factor is a highly discriminatory biomarker for the diagnosis of rheumatoid arthritis

Abstract Background Our previous proteomic study indicated that connective tissue growth factor (CTGF) may be a potential biomarker for rheumatoid arthritis (RA) diagnosis. The aim was to assess the performance of CTGF as a biomarker of RA. Method Serum and synovial fluid CTGF was detected using a d... Full description

Journal Title: Arthritis Research & Therapy 01 November 2017, Vol.19(1), pp.1-9
Main Author: Xinyu Yang
Other Authors: Ke Lin , Shanmin Ni , Jianmin Wang , Qingqing Tian , Huaijun Chen , Matthew A. Brown , Kaidi Zheng , Weitao Zhai , Li Sun , Shengwei Jin , Jianguang Wang
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: E-ISSN: 1478-6362 ; DOI: 10.1186/s13075-017-1463-1
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: doaj_soai_doaj_org_article_828fc720f7ca4dd28a537bf9096fd49e
title: Serum connective tissue growth factor is a highly discriminatory biomarker for the diagnosis of rheumatoid arthritis
format: Article
creator:
  • Xinyu Yang
  • Ke Lin
  • Shanmin Ni
  • Jianmin Wang
  • Qingqing Tian
  • Huaijun Chen
  • Matthew A. Brown
  • Kaidi Zheng
  • Weitao Zhai
  • Li Sun
  • Shengwei Jin
  • Jianguang Wang
subjects:
  • Rheumatoid Arthritis
  • Ctgf
  • Acpa
  • Rheumatoid Factor
  • Biomarker
  • Medicine
ispartof: Arthritis Research & Therapy, 01 November 2017, Vol.19(1), pp.1-9
description: Abstract Background Our previous proteomic study indicated that connective tissue growth factor (CTGF) may be a potential biomarker for rheumatoid arthritis (RA) diagnosis. The aim was to assess the performance of CTGF as a biomarker of RA. Method Serum and synovial fluid CTGF was detected using a direct high sensitivity sandwich ELISA kit. Serum CTGF levels were tested for discriminatory capacity and optimal assay cutoffs determined in a training cohort of 98 cases of RA with 103 healthy controls. The assay performance was then validated in a further cohort of 572 patients (with RA (n = 217), ankylosing spondylitis (n = 92), gout (n = 74), osteoarthritis (n = 52), systemic lupus erythematosus (n = 72), or primary Sjögren’s syndrome (pSS) (n = 65)). Results Significant elevation of synovial fluid CTGF concentration was found in RA patients, demonstrating excellent diagnostic ability to predict RA (area under the curve (AUC) = 0.97). Similar results were found in serum CTGF detection. At the optimal cutoff value 88.66 pg/mL, the sensitivity, specificity, and the AUC was 0.86, 0.92, and 0.92, respectively, in the training cohort. Similar performance was observed in the validation cohort, with sensitivity, specificity, positive likelihood, and negative likelihood of 0.82, 0.91, 5.74, and 0.12, respectively. Stronger discriminatory capacity was seen with the combination of CTGF and anti-citrullinated protein antibody (ACPA) (AUC = 0.96) than with either ACPA or rheumatoid factor (RF) alone (AUC = 0.80 or 0.79, respectively). The discriminatory performance of serum CTGF was consistent across all inflammatory conditions tested (AUC >0.92 in all cases), with the sole exception of pSS. Serum CTGF did not vary with symptom duration or disease activity. Conclusions Serum CTGF is a promising diagnostic biomarker for RA, with performance in the current study better than either ACPA or RF.
language: eng
source:
identifier: E-ISSN: 1478-6362 ; DOI: 10.1186/s13075-017-1463-1
fulltext: fulltext_linktorsrc
issn:
  • 1478-6362
  • 14786362
url: Link


@attributes
ID1060182510
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordidoai_doaj_org_article_828fc720f7ca4dd28a537bf9096fd49e
sourceiddoaj_s
recordidTN_doaj_soai_doaj_org_article_828fc720f7ca4dd28a537bf9096fd49e
sourcesystemOther
dbidDOA
pqid1973334906
galeid546247205
display
typearticle
titleSerum connective tissue growth factor is a highly discriminatory biomarker for the diagnosis of rheumatoid arthritis
creatorXinyu Yang ; Ke Lin ; Shanmin Ni ; Jianmin Wang ; Qingqing Tian ; Huaijun Chen ; Matthew A. Brown ; Kaidi Zheng ; Weitao Zhai ; Li Sun ; Shengwei Jin ; Jianguang Wang
ispartofArthritis Research & Therapy, 01 November 2017, Vol.19(1), pp.1-9
identifierE-ISSN: 1478-6362 ; DOI: 10.1186/s13075-017-1463-1
subjectRheumatoid Arthritis ; Ctgf ; Acpa ; Rheumatoid Factor ; Biomarker ; Medicine
descriptionAbstract Background Our previous proteomic study indicated that connective tissue growth factor (CTGF) may be a potential biomarker for rheumatoid arthritis (RA) diagnosis. The aim was to assess the performance of CTGF as a biomarker of RA. Method Serum and synovial fluid CTGF was detected using a direct high sensitivity sandwich ELISA kit. Serum CTGF levels were tested for discriminatory capacity and optimal assay cutoffs determined in a training cohort of 98 cases of RA with 103 healthy controls. The assay performance was then validated in a further cohort of 572 patients (with RA (n = 217), ankylosing spondylitis (n = 92), gout (n = 74), osteoarthritis (n = 52), systemic lupus erythematosus (n = 72), or primary Sjögren’s syndrome (pSS) (n = 65)). Results Significant elevation of synovial fluid CTGF concentration was found in RA patients, demonstrating excellent diagnostic ability to predict RA (area under the curve (AUC) = 0.97). Similar results were found in serum CTGF detection. At the optimal cutoff value 88.66 pg/mL, the sensitivity, specificity, and the AUC was 0.86, 0.92, and 0.92, respectively, in the training cohort. Similar performance was observed in the validation cohort, with sensitivity, specificity, positive likelihood, and negative likelihood of 0.82, 0.91, 5.74, and 0.12, respectively. Stronger discriminatory capacity was seen with the combination of CTGF and anti-citrullinated protein antibody (ACPA) (AUC = 0.96) than with either ACPA or rheumatoid factor (RF) alone (AUC = 0.80 or 0.79, respectively). The discriminatory performance of serum CTGF was consistent across all inflammatory conditions tested (AUC >0.92 in all cases), with the sole exception of pSS. Serum CTGF did not vary with symptom duration or disease activity. Conclusions Serum CTGF is a promising diagnostic biomarker for RA, with performance in the current study better than either ACPA or RF.
languageeng
oafree_for_read
source
version8
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
linktorsrc$$Uhttps://doaj.org/article/828fc720f7ca4dd28a537bf9096fd49e$$EView_full_text_in_DOAJ
search
creatorcontrib
0Xinyu Yang
1Ke Lin
2Shanmin Ni
3Jianmin Wang
4Qingqing Tian
5Huaijun Chen
6Matthew A. Brown
7Kaidi Zheng
8Weitao Zhai
9Li Sun
10Shengwei Jin
11Jianguang Wang
titleSerum connective tissue growth factor is a highly discriminatory biomarker for the diagnosis of rheumatoid arthritis
description

Abstract Background Our previous proteomic study indicated that connective tissue growth factor (CTGF) may be a potential biomarker for rheumatoid arthritis (RA) diagnosis. The aim was to assess the performance of CTGF as a biomarker of RA. Method Serum and synovial fluid CTGF was detected using a direct high sensitivity sandwich ELISA kit. Serum CTGF levels were tested for discriminatory capacity and optimal assay cutoffs determined in a training cohort of 98 cases of RA with 103 healthy controls. The assay performance was then validated in a further cohort of 572 patients (with RA (n = 217), ankylosing spondylitis (n = 92), gout (n = 74), osteoarthritis (n = 52), systemic lupus erythematosus (n = 72), or primary Sjögren’s syndrome (pSS) (n = 65)). Results Significant elevation of synovial fluid CTGF concentration was found in RA patients, demonstrating excellent diagnostic ability to predict RA (area under the curve (AUC) = 0.97). Similar results were found in serum CTGF detection. At the optimal cutoff value 88.66 pg/mL, the sensitivity, specificity, and the AUC was 0.86, 0.92, and 0.92, respectively, in the training cohort. Similar performance was observed in the validation cohort, with sensitivity, specificity, positive likelihood, and negative likelihood of 0.82, 0.91, 5.74, and 0.12, respectively. Stronger discriminatory capacity was seen with the combination of CTGF and anti-citrullinated protein antibody (ACPA) (AUC = 0.96) than with either ACPA or rheumatoid factor (RF) alone (AUC = 0.80 or 0.79, respectively). The discriminatory performance of serum CTGF was consistent across all inflammatory conditions tested (AUC >0.92 in all cases), with the sole exception of pSS. Serum CTGF did not vary with symptom duration or disease activity. Conclusions Serum CTGF is a promising diagnostic biomarker for RA, with performance in the current study better than either ACPA or RF.

subject
0Rheumatoid Arthritis
1Ctgf
2Acpa
3Rheumatoid Factor
4Biomarker
5Medicine
general
0English
1BMC
210.1186/s13075-017-1463-1
3Directory of Open Access Journals (DOAJ)
sourceiddoaj_s
recordiddoaj_soai_doaj_org_article_828fc720f7ca4dd28a537bf9096fd49e
issn
01478-6362
114786362
rsrctypearticle
creationdate2017
addtitleArthritis Research & Therapy
searchscope
0doaj_full
1doaj1
scope
0doaj_full
1doaj1
lsr45$$EView_full_text_in_DOAJ
tmp01Directory of Open Access Journals (DOAJ)
tmp02DOA
startdate20171101
enddate20171101
lsr40Arthritis Research & Therapy, 01 November 2017, Vol.19 (1), pp.1-9
doi10.1186/s13075-017-1463-1
citationpf 1 pt 9 vol 19 issue 1
lsr30VSR-Enriched:[pqid, issn, galeid]
sort
titleSerum connective tissue growth factor is a highly discriminatory biomarker for the diagnosis of rheumatoid arthritis
authorXinyu Yang ; Ke Lin ; Shanmin Ni ; Jianmin Wang ; Qingqing Tian ; Huaijun Chen ; Matthew A. Brown ; Kaidi Zheng ; Weitao Zhai ; Li Sun ; Shengwei Jin ; Jianguang Wang
creationdate20171101
lso0120171101
facets
frbrgroupid-1876022557230243940
frbrtype5
newrecords20190714
languageeng
topic
0Rheumatoid Arthritis
1Ctgf
2Acpa
3Rheumatoid Factor
4Biomarker
5Medicine
collectionDirectory of Open Access Journals (DOAJ)
prefilterarticles
rsrctypearticles
creatorcontrib
0Xinyu Yang
1Ke Lin
2Shanmin Ni
3Jianmin Wang
4Qingqing Tian
5Huaijun Chen
6Matthew A. Brown
7Kaidi Zheng
8Weitao Zhai
9Li Sun
10Shengwei Jin
11Jianguang Wang
jtitleArthritis Research & Therapy
creationdate2017
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext_linktorsrc
addata
au
0Xinyu Yang
1Ke Lin
2Shanmin Ni
3Jianmin Wang
4Qingqing Tian
5Huaijun Chen
6Matthew A. Brown
7Kaidi Zheng
8Weitao Zhai
9Li Sun
10Shengwei Jin
11Jianguang Wang
atitleSerum connective tissue growth factor is a highly discriminatory biomarker for the diagnosis of rheumatoid arthritis
jtitleArthritis Research & Therapy
risdate20171101
volume19
issue1
spage1
epage9
pages1-9
eissn1478-6362
formatjournal
genrearticle
ristypeJOUR
abstract

Abstract Background Our previous proteomic study indicated that connective tissue growth factor (CTGF) may be a potential biomarker for rheumatoid arthritis (RA) diagnosis. The aim was to assess the performance of CTGF as a biomarker of RA. Method Serum and synovial fluid CTGF was detected using a direct high sensitivity sandwich ELISA kit. Serum CTGF levels were tested for discriminatory capacity and optimal assay cutoffs determined in a training cohort of 98 cases of RA with 103 healthy controls. The assay performance was then validated in a further cohort of 572 patients (with RA (n = 217), ankylosing spondylitis (n = 92), gout (n = 74), osteoarthritis (n = 52), systemic lupus erythematosus (n = 72), or primary Sjögren’s syndrome (pSS) (n = 65)). Results Significant elevation of synovial fluid CTGF concentration was found in RA patients, demonstrating excellent diagnostic ability to predict RA (area under the curve (AUC) = 0.97). Similar results were found in serum CTGF detection. At the optimal cutoff value 88.66 pg/mL, the sensitivity, specificity, and the AUC was 0.86, 0.92, and 0.92, respectively, in the training cohort. Similar performance was observed in the validation cohort, with sensitivity, specificity, positive likelihood, and negative likelihood of 0.82, 0.91, 5.74, and 0.12, respectively. Stronger discriminatory capacity was seen with the combination of CTGF and anti-citrullinated protein antibody (ACPA) (AUC = 0.96) than with either ACPA or rheumatoid factor (RF) alone (AUC = 0.80 or 0.79, respectively). The discriminatory performance of serum CTGF was consistent across all inflammatory conditions tested (AUC >0.92 in all cases), with the sole exception of pSS. Serum CTGF did not vary with symptom duration or disease activity. Conclusions Serum CTGF is a promising diagnostic biomarker for RA, with performance in the current study better than either ACPA or RF.

pubBMC
doi10.1186/s13075-017-1463-1
oafree_for_read
issn14786354
date2017-11-01